{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:03:08Z","timestamp":1768438988784,"version":"3.49.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ctrv.2016.09.013","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T03:53:23Z","timestamp":1474430003000},"page":"183-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials"],"prefix":"10.1016","volume":"50","author":[{"given":"Nathalie","family":"LeVasseur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmel","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2016.09.013_b0010","unstructured":"Ferlay J, Shin HR, Bray F, et al. Cancer incidence and mortality worldwide: IARC Cancer Base NO. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. Available at http:\/\/globocan.iarc.fr. Accessed August 6; 2015."},{"issue":"21","key":"10.1016\/j.ctrv.2016.09.013_b0015","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0020","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1634\/theoncologist.2011-0079","article-title":"Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer","volume":"16","author":"Yu","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2016.09.013_b0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0030","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2016.09.013_b0035","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.ctrv.2016.09.013_b0040","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2016.09.013_b0045","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00520-011-1230-9","article-title":"Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists","volume":"19","author":"Bouganim","year":"2011","journal-title":"Support Care Cancer"},{"issue":"35","key":"10.1016\/j.ctrv.2016.09.013_b0050","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.09.013_b0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","article-title":"Burden of skeletal-related events in prostate cancer: unmet need in pain improvement","volume":"23","author":"Broder","year":"2015","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2016.09.013_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.09.010","article-title":"The burden of skeletal-related events in patients with prostate cancer and bone metastasis","volume":"33","author":"Roghmann","year":"2015","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2016.09.013_b0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0305-7372(85)90008-8","article-title":"Bone metastases and breast cancer","volume":"12","author":"Coleman","year":"1985","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.ctrv.2016.09.013_b0070","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0075","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-0981-1","article-title":"Prognostic factors for skeletal complications from metastatic bone disease in breast cancer","volume":"123","author":"Brown","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ctrv.2016.09.013_b0080","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00520-013-2094-y","article-title":"Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems","volume":"22","author":"Oster","year":"2014","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0085","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J Thoracic Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2016.09.013_b0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jbo.2012.12.004","article-title":"Incidence and consequences of bone metastases in lung cancer patients","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J Bone Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.09.013_b0095","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: a retrospective study","volume":"57","author":"Tsuya","year":"2007","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2016.09.013_b0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2010.04.003","article-title":"Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases","volume":"71","author":"Sun","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.09.013_b0105","unstructured":"Hei Y-J, Saad F, Coleman RE, et al. Fractures negatively affect survival in patients with bone metastases from breast cancer. In: Poster presented at: 28th annual San Antonio breast cancer symposium (SABCS); December 8\u201311,2005; San Antonio, TX. Abstract 6036; 2005."},{"key":"10.1016\/j.ctrv.2016.09.013_b0110","doi-asserted-by":"crossref","unstructured":"Saad F, Chen Y, Hei Y-J. Fractures negatively impact survival in patients with multiple myeloma or bone metastases from solid tumors. In: Poster presented at: 13th European conference on clinical oncology (ECCO); October 30\u2013November 3, 2005. Paris, France. Abstract 1265; 2005.","DOI":"10.1016\/S1359-6349(05)81558-7"},{"issue":"Suppl 3","key":"10.1016\/j.ctrv.2016.09.013_b0115","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/annonc\/mdu199","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Reck","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2016.09.013_b0120","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2016.09.013_b0125","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0130","unstructured":"Emmenegger U, Agbassi, C, reviewers. Program in Evidence-based Care. The use of bisphosphonates in men with hormone-refractory prostate cancer. Cancer Care Ontario; 2012 Jun 21 [Archived 2012 Mar]. Program in Evidence-based Care Evidence-based Series No.: 3\u201314 ARCHIVED; 2012."},{"issue":"9","key":"10.1016\/j.ctrv.2016.09.013_b0135","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jclinepi.2008.10.012","article-title":"An evidence-based practice guideline for the peer review of electronic search strategies","volume":"62","author":"Sampson","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0140","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2016.09.013_b0145","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clin Res ed)."},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thoracic Oncol"},{"issue":"S8","key":"10.1016\/j.ctrv.2016.09.013_b0155","first-page":"viii286","article-title":"Efficacy and safety of intravenous zoledronic acid (ZA) 4 MG infused over 15minutes: results from a 2-year study of lung cancer patients (LCP) with metastatic bone disease","volume":"19","author":"Kritikos","year":"2008","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2016.09.013_b0160","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2016.09.013_b0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1525-7304(11)70347-3","article-title":"Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases","volume":"5","author":"Price","year":"2004","journal-title":"Clin Lung Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2016.09.013_b0170","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.09.013_b0175","first-page":"213","article-title":"A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy","volume":"17","author":"Piga","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2016.09.013_b0180","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1995.13.9.2427","article-title":"Effect of oral clodronate on metastatic bone pain: a double blind, placebo controlled study","volume":"13","author":"Robertson","year":"1995","journal-title":"J Clin Oncol"},{"issue":"SUPPL. 3","key":"10.1016\/j.ctrv.2016.09.013_b0185","first-page":"S203","article-title":"Comparative efficacy of ibandronic acid vs. Zoledronic acid in lung cancer patients with skeletal metastases. Do they alleviate the patient?","volume":"9","author":"Dimitroulis","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0190","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10147-010-0179-x","article-title":"Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer","volume":"16","author":"Francini","year":"2011","journal-title":"Int J Clin Oncol"},{"issue":"15 SUPPL. 1","key":"10.1016\/j.ctrv.2016.09.013_b0195","doi-asserted-by":"crossref","first-page":"e20524","DOI":"10.1200\/jco.2009.27.15_suppl.e20524","article-title":"The better bisphosphonate in patient with bone metastasis: zoledronic acid or ibandronic acid? A study from Eastern India","volume":"27","author":"Pandey","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2016.09.013_b0200","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00432-008-0419-x","article-title":"Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease","volume":"134","author":"Mystakidou","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0205","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","article-title":"Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease","volume":"12","author":"Jagdev","year":"2001","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2016.09.013_b0210","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/cas.12448","article-title":"Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group","volume":"105","author":"Murakami","year":"2014","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.ctrv.2016.09.013_b0215","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.ctrv.2016.09.013_b0220","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0225","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized double blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) and multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0230","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cllc.2012.09.001","article-title":"Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer","volume":"14","author":"Wang","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2016.09.013_b0235","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0240","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.09.013_b0245","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0250","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0255","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2016.09.013_b0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","article-title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer","volume":"4","author":"Saad","year":"2005","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.ctrv.2016.09.013_b0265","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.09.013_b0270","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.09.013_b0275","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. v.2.2011:MS37-MS39. Available at: <http:\/\/www.nccn.org>. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed April 8, 2015."},{"key":"10.1016\/j.ctrv.2016.09.013_b0280","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. v.4.2011:MS22-MS23. Available at: <http:\/\/www.nccn.org>. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed April 8, 2015."},{"key":"10.1016\/j.ctrv.2016.09.013_b0285","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. v.1.2012:MS24-MS25. Available at: <http:\/\/www.nccn.org>. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed April 8, 2015."},{"issue":"suppl 3","key":"10.1016\/j.ctrv.2016.09.013_b0290","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0295","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.09.013_b0300","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/JTO.0b013e31819518fc","article-title":"Prevention and management of bone metastases in lung cancer: a review","volume":"4","author":"Al Husaini","year":"2009","journal-title":"J Thoracic Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0305","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/fon.10.192","article-title":"Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?","volume":"7","author":"Bouganim","year":"2011","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2016.09.013_b0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jbo.2013.03.001","article-title":"De-escalated administration of bone-targeted agents in patients with breast and prostate cancer \u2013 a survey of Canadian oncologists.","volume":"2","author":"Hutton","year":"2013","journal-title":"J Bone Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2013.05.001","article-title":"A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer","volume":"2","author":"Hutton","year":"2013","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0320","unstructured":"European Cancer Congress 2013 (ECCO-ESMO-ESTRO) [Internet]. Amsterdam, The Netherlands; September 27th\u2013October 1st, 2013. Available at: http:\/\/www.kantarhealth.com\/docs\/publications-citations\/insights-into-the-management-of-bone-metastases-in-patients-with-lung-cancer-a-comprehensive-european-survey. Accessed March 25, 2015."},{"issue":"11","key":"10.1016\/j.ctrv.2016.09.013_b0325","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00520-012-1563-z","article-title":"Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis","volume":"20","author":"Lopez-Olivo","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2016.09.013_b0330","unstructured":"Amgen. Denosumab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer. In: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US) 2000 \u2013 [Internet]. Last accessed Dec 4, 2015 from: <https:\/\/www.clinicaltrial.gov\/ct2\/show\/NCT01951586?term=denosumab&rank=20>."},{"key":"10.1016\/j.ctrv.2016.09.013_b0335","unstructured":"European Thoracic Oncology Platform. Survival Improvement in Lung Cancer Induced by Denosumab therapy (SPLENDOUR). In: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US) 2000 \u2013 [Internet]. Last accessed Dec 4, 2015 from: <https:\/\/www.clinicaltrial.gov\/ct2\/show\/NCT02129699?term=denosumab&rank=21>."},{"key":"10.1016\/j.ctrv.2016.09.013_b0340","unstructured":"GlaxoSmithKline. A study to compare denosumab with zoledronic acid in subjects with bone metastases from solid tumors. In: ClinicalTrials.gov (Internet). Bethesda (MD): National Library of Medicine (US) 2000 \u2013 [Internet]. Last accessed Dec 4, 2015 from: https:\/\/www.clinicaltrial.gov\/ct2\/show\/NCT01920568?term=denosumab&rank=40."},{"issue":"9","key":"10.1016\/j.ctrv.2016.09.013_b0350","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2016.09.013_b0355","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma","volume":"24","author":"Aviles","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0360","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.ctrv.2016.09.013_b0365","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S1040-8428(11)70006-3","article-title":"Anticancer evidence for zoledronic acid across the cancer continuum","volume":"77","author":"Costa","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2016.09.013_b0370","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"Coleman","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.ctrv.2016.09.013_b0375","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2016.09.013_b0380","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jbo.2012.09.001","article-title":"A national portfolio of bone oncology trials \u2013 the Canadian experience in 2012","volume":"1","author":"Kuchuk","year":"2012","journal-title":"J Bone Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:54:35Z","timestamp":1601096075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216300937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":75,"alternative-id":["S0305737216300937"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.013","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}